Extracellular vesicles may drive fibrosis in scleroderma

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

Com­bined with chemother­a­py and im­munother­a­py, As­traZeneca’s Calquence re­duced the risk of dis­ease pro­gres­sion or death by 27% com­pared to place­bo and chemoim­munother­a­py in first-line man­tle